FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052968476> ?p ?o ?g. }

• W2052968476 endingPage "e52" @default.
• W2052968476 startingPage "e51" @default.
• W2052968476 abstract "ObjectiveThe study objective was to determine if Anti-Mullerian Hormone (AMH) levels decline following gonadotoxic therapy in pediatric and adolescent females with cancer as compared to the reported decline demonstrated in adult women. We compared AMH levels in newly diagnosed cancer patients to healthy controls.DesignProspective cohort study.Materials and MethodsConsent and/or assent were obtained via the University of Iowa IRB. Data and samples were collected from control and affected cases at the University of Iowa Hospitals & Clinics over 16 months. Enzyme-linked immunosorbent assays (ELISA) of AMH were performed using the GenII assay (Becton Dickinson). AMH levels were measured in affected cases at baseline and 3 months post-treatment (chemotherapy or radiation). Baseline AMH levels were compared to healthy controls recruited from the pediatric clinic. Linear regression models were constructed using regression identified and clinically significant confounding variables with AMH as the dependent variable. Chi square was used for categorical variables and Student’s t-test or ANOVA was utilized for continuous variables. All variables were tested at significance level of 0.05.ResultsSamples were collected from 104 healthy controls, 10 cases at baseline, and 5 cases at 3 months post-treatment. No statistically significant difference was observed at baseline between cases and controls. The average AMH concentration (ng/ml) was 2.3 +/- 0.21 in controls, 1.8 +/- 0.30 in affected cases at baseline, and 0.60 +/- 0.36 at 3 months post-treatment. No significant differences in between groups were observed in age at sample collection, race, body mass index, age at menarche, menarche status or Tanner stage.ConclusionCancer alone does not result in a statistically significant decrease in AMH levels in pediatric and adolescent females; however, post-treatment AMH levels are reduced significantly, as expected. These findings are similar to that seen in the adult female cancer population. Results from this study will contribute to determining the use of AMH as a biomarker of fertility for female pediatric and adolescent cancer patients. Validating a viable biomarker will be critical to identifying fertility preservation methods in young female oncology patients. ObjectiveThe study objective was to determine if Anti-Mullerian Hormone (AMH) levels decline following gonadotoxic therapy in pediatric and adolescent females with cancer as compared to the reported decline demonstrated in adult women. We compared AMH levels in newly diagnosed cancer patients to healthy controls. The study objective was to determine if Anti-Mullerian Hormone (AMH) levels decline following gonadotoxic therapy in pediatric and adolescent females with cancer as compared to the reported decline demonstrated in adult women. We compared AMH levels in newly diagnosed cancer patients to healthy controls. DesignProspective cohort study. Prospective cohort study. Materials and MethodsConsent and/or assent were obtained via the University of Iowa IRB. Data and samples were collected from control and affected cases at the University of Iowa Hospitals & Clinics over 16 months. Enzyme-linked immunosorbent assays (ELISA) of AMH were performed using the GenII assay (Becton Dickinson). AMH levels were measured in affected cases at baseline and 3 months post-treatment (chemotherapy or radiation). Baseline AMH levels were compared to healthy controls recruited from the pediatric clinic. Linear regression models were constructed using regression identified and clinically significant confounding variables with AMH as the dependent variable. Chi square was used for categorical variables and Student’s t-test or ANOVA was utilized for continuous variables. All variables were tested at significance level of 0.05. Consent and/or assent were obtained via the University of Iowa IRB. Data and samples were collected from control and affected cases at the University of Iowa Hospitals & Clinics over 16 months. Enzyme-linked immunosorbent assays (ELISA) of AMH were performed using the GenII assay (Becton Dickinson). AMH levels were measured in affected cases at baseline and 3 months post-treatment (chemotherapy or radiation). Baseline AMH levels were compared to healthy controls recruited from the pediatric clinic. Linear regression models were constructed using regression identified and clinically significant confounding variables with AMH as the dependent variable. Chi square was used for categorical variables and Student’s t-test or ANOVA was utilized for continuous variables. All variables were tested at significance level of 0.05. ResultsSamples were collected from 104 healthy controls, 10 cases at baseline, and 5 cases at 3 months post-treatment. No statistically significant difference was observed at baseline between cases and controls. The average AMH concentration (ng/ml) was 2.3 +/- 0.21 in controls, 1.8 +/- 0.30 in affected cases at baseline, and 0.60 +/- 0.36 at 3 months post-treatment. No significant differences in between groups were observed in age at sample collection, race, body mass index, age at menarche, menarche status or Tanner stage. Samples were collected from 104 healthy controls, 10 cases at baseline, and 5 cases at 3 months post-treatment. No statistically significant difference was observed at baseline between cases and controls. The average AMH concentration (ng/ml) was 2.3 +/- 0.21 in controls, 1.8 +/- 0.30 in affected cases at baseline, and 0.60 +/- 0.36 at 3 months post-treatment. No significant differences in between groups were observed in age at sample collection, race, body mass index, age at menarche, menarche status or Tanner stage. ConclusionCancer alone does not result in a statistically significant decrease in AMH levels in pediatric and adolescent females; however, post-treatment AMH levels are reduced significantly, as expected. These findings are similar to that seen in the adult female cancer population. Results from this study will contribute to determining the use of AMH as a biomarker of fertility for female pediatric and adolescent cancer patients. Validating a viable biomarker will be critical to identifying fertility preservation methods in young female oncology patients. Cancer alone does not result in a statistically significant decrease in AMH levels in pediatric and adolescent females; however, post-treatment AMH levels are reduced significantly, as expected. These findings are similar to that seen in the adult female cancer population. Results from this study will contribute to determining the use of AMH as a biomarker of fertility for female pediatric and adolescent cancer patients. Validating a viable biomarker will be critical to identifying fertility preservation methods in young female oncology patients." @default.
• W2052968476 created "2016-06-24" @default.
• W2052968476 creator A5006764509 @default.
• W2052968476 creator A5011911130 @default.
• W2052968476 creator A5012714298 @default.
• W2052968476 creator A5015401066 @default.
• W2052968476 creator A5025165376 @default.
• W2052968476 creator A5052964878 @default.
• W2052968476 creator A5070818122 @default.
• W2052968476 creator A5074358152 @default.
• W2052968476 creator A5091395066 @default.
• W2052968476 date "2014-09-01" @default.
• W2052968476 modified "2023-09-27" @default.
• W2052968476 title "Cancer treatment negatively impacts anti-mullerian hormone in pediatric and adolescent females" @default.
• W2052968476 doi "https://doi.org/10.1016/j.fertnstert.2014.07.179" @default.
• W2052968476 hasPublicationYear "2014" @default.
• W2052968476 type Work @default.
• W2052968476 sameAs 2052968476 @default.
• W2052968476 citedByCount "0" @default.
• W2052968476 crossrefType "journal-article" @default.
• W2052968476 hasAuthorship W2052968476A5006764509 @default.
• W2052968476 hasAuthorship W2052968476A5011911130 @default.
• W2052968476 hasAuthorship W2052968476A5012714298 @default.
• W2052968476 hasAuthorship W2052968476A5015401066 @default.
• W2052968476 hasAuthorship W2052968476A5025165376 @default.
• W2052968476 hasAuthorship W2052968476A5052964878 @default.
• W2052968476 hasAuthorship W2052968476A5070818122 @default.
• W2052968476 hasAuthorship W2052968476A5074358152 @default.
• W2052968476 hasAuthorship W2052968476A5091395066 @default.
• W2052968476 hasBestOaLocation W20529684761 @default.
• W2052968476 hasConcept C121608353 @default.
• W2052968476 hasConcept C126322002 @default.
• W2052968476 hasConcept C188816634 @default.
• W2052968476 hasConcept C2778780466 @default.
• W2052968476 hasConcept C2780221984 @default.
• W2052968476 hasConcept C29456083 @default.
• W2052968476 hasConcept C2983394010 @default.
• W2052968476 hasConcept C71315377 @default.
• W2052968476 hasConcept C71924100 @default.
• W2052968476 hasConcept C77350462 @default.
• W2052968476 hasConcept C99476002 @default.
• W2052968476 hasConceptScore W2052968476C121608353 @default.
• W2052968476 hasConceptScore W2052968476C126322002 @default.
• W2052968476 hasConceptScore W2052968476C188816634 @default.
• W2052968476 hasConceptScore W2052968476C2778780466 @default.
• W2052968476 hasConceptScore W2052968476C2780221984 @default.
• W2052968476 hasConceptScore W2052968476C29456083 @default.
• W2052968476 hasConceptScore W2052968476C2983394010 @default.
• W2052968476 hasConceptScore W2052968476C71315377 @default.
• W2052968476 hasConceptScore W2052968476C71924100 @default.
• W2052968476 hasConceptScore W2052968476C77350462 @default.
• W2052968476 hasConceptScore W2052968476C99476002 @default.
• W2052968476 hasIssue "3" @default.
• W2052968476 hasLocation W20529684761 @default.
• W2052968476 hasOpenAccess W2052968476 @default.
• W2052968476 hasPrimaryLocation W20529684761 @default.
• W2052968476 hasRelatedWork W1978284068 @default.
• W2052968476 hasRelatedWork W1999344589 @default.
• W2052968476 hasRelatedWork W2076356724 @default.
• W2052968476 hasRelatedWork W2109155080 @default.
• W2052968476 hasRelatedWork W2589183872 @default.
• W2052968476 hasRelatedWork W2760047697 @default.
• W2052968476 hasRelatedWork W2789448498 @default.
• W2052968476 hasRelatedWork W3014043640 @default.
• W2052968476 hasRelatedWork W3137702297 @default.
• W2052968476 hasRelatedWork W4310493648 @default.
• W2052968476 hasVolume "102" @default.
• W2052968476 isParatext "false" @default.
• W2052968476 isRetracted "false" @default.
• W2052968476 magId "2052968476" @default.
• W2052968476 workType "article" @default.